Through the Boston Pharma deal, GSK aims to strengthen its pipeline, as some of its key products are nearing the end of their exclusivity period.

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

GSK's new long-acting drug candidate for severe asthma, depemokimab, reduced the rate of severe attacks by 54% in a pair of phase 3 trials presented at the European Respiratory Society (ERS ...

GSK said it remains confident it can absorb the financial impact of potential US tariffs as it posted a 4% rise in Q1 2025 ...

GSK (LSE:GSK) reported a significant improvement in its first-quarter earnings, with sales, net income, and earnings per share all showing promising growth. This announcement coincided with a 5.14% ...

GSK plc GSK announced that it has signed an ... on the remaining three — Blenrep (relaunch in multiple myeloma), depemokimab (for severe asthma and chronic rhinosinusitis with nasal polyps ...

GSK to present data from across its respiratory portfolio at 2025 ATS International Congress in San Francisco: London, UK Monday, May 5, 2025, 10:00 Hrs [IST] GSK plc announced da ...

Despite its profile as a long-acting IL-5 receptor antagonist with convenient semiannual dosing, GSK's depemokimab, the most advanced asthma pipeline asset, has generated relatively limited ...